PT  - JOURNAL ARTICLE
AU  - Shuo Li
AU  - Zorawar Noor
AU  - Weihua Zeng
AU  - Xiaohui Ni
AU  - Zuyang Yuan
AU  - Frank Alber
AU  - Wenyuan Li
AU  - Edward B. Garon
AU  - Xianghong Jasmine Zhou
TI  - Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis
AID  - 10.1101/2019.12.31.19016253
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2019.12.31.19016253
4099  - http://medrxiv.org/content/early/2020/01/03/2019.12.31.19016253.short
4100  - http://medrxiv.org/content/early/2020/01/03/2019.12.31.19016253.full
AB  - Liquid biopsy using cell-free DNA (cfDNA) is attractive for a wide range of clinical applications, including cancer detection, locating, and monitoring. However, developing these applications requires precise and sensitive calling of somatic single nucleotide variations (SNVs) from cfDNA sequencing data. To date, no SNV caller addresses all the special challenges of cfDNA to provide reliable results. Here we present cfSNV, a revolutionary somatic SNV caller with five innovative techniques to overcome and exploit the unique properties of cfDNA. cfSNV provides hierarchical mutation profiling, thanks to cfDNA’s complete coverage of the clonal landscape, and multi-layer error suppression. In both simulated datasets and real patient data, we demonstrate that cfSNV is superior to existing tools, especially for low-frequency somatic SNVs. We also show how the five novel techniques contribute to its performance. Further, we demonstrate a clinical application using cfSNV to select non-small-cell lung cancer patients for immunotherapy treatment.Competing Interest StatementX.J.Z. and W.L. are co-founders and X.N. is the CTO of EarlyDiagnostics, Inc. The authors declare no competing interests.Funding StatementNIH grant U01CA230705 to X.J.Z., U01CA237711 to W.L., and R01CA246329 to X.J.Z. and W.L. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data related to this manuscript can be provided upon request. The links to public data are included in Methods.